دورية أكاديمية
Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients
| العنوان: | Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients |
|---|---|
| المؤلفون: | Nazzaro, G, Carugno, A, Bortoluzzi, P, Buffon, S, Astrua, C, Zappia, E, Trovato, E, Caccavale, S, Pellegrino, V, Paolino, G, Balestri, R, Lacava, R, Ciccarese, G, Verdelli, A, Barruscotti, S, Valenti, M, Toni, G, Giacalone, S, Zavattaro, E, Gironi, LC, Mercuri, SR, Ribero, S, Gisondi, P, Sena, P, Marzano, AV |
| المساهمون: | Nazzaro, G, Carugno, A, Bortoluzzi, P, Buffon, S, Astrua, C, Zappia, E, Trovato, E, Caccavale, S, Pellegrino, V, Paolino, G, Balestri, R, Lacava, R, Ciccarese, G, Verdelli, A, Barruscotti, S, Valenti, M, Toni, G, Giacalone, S, Zavattaro, E, Gironi, L, Mercuri, S, Ribero, S, Gisondi, P, Sena, P, Marzano, A |
| بيانات النشر: | Blackwell Science Limited US |
| سنة النشر: | 2024 |
| المجموعة: | Università degli Studi di Milano-Bicocca: BOA (Bicocca Open Archive) |
| مصطلحات موضوعية: | actinic keratosi, cancerization field, efficacy, real‐life, tirbanibulin, tolerability |
| الوصف: | Background: Tirbanibulin 1% ointment is approved for the field treatment of Olsen grade I actinic keratoses (AKs) of the face and scalp. Methods: We performed a multicenter retrospective study involving 15 dermatologic units in Italy to investigate the efficacy and tolerability of tirbanibulin in a real-life setting. 250 patients were enrolled. Tirbanibulin, 1% ointment, was applied daily for five consecutive days. The efficacy of treatment was measured with modifications of the Actinic Keratosis Area and Severity Index (AKASI). A satisfactory response was defined by complete (100% reduction in the number of lesions) or partial clearance (75-99%) of treated AKs. Results: Overall, the AKASI score was significantly reduced in the studied population (mean, from 4.1 ± 2.7 to 1.4 ± 1.5; P < 0.001). A satisfactory response was observed in 222 (88.8%) cases. The proportion of satisfactory responses was higher when follow-up was performed after 8 weeks (34/35, 97.1%). The reduction in AKASI was significant in patients with Olsen grade II or III lesions (from 5.3 ± 2.8 to 1.6 ± 1.6; P < 0.001). A satisfactory response was observed in 91/104 (87.5%) cases. AKASI reduction was also significant in patients with trunk or limb AKs (from 7.0 ± 1.3 to 2.0 ± 1.6; P = 0.018) since a satisfactory response was observed in 7/8 (87.5%) cases. Tirbanibulin was well tolerated; all adverse events (AEs) included transient local reactions at the site of treatment. Overall, 231 patients had at least one AE. Only 7 (2.8%) grade 4 AEs were recorded. Conclusion: Our retrospective study confirmed that tirbanibulin 1% ointment is effective and well tolerated in a real-life setting and is also promising for Olsen grade II and grade III AKs and AKs localized on difficult-to-treat areas. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/38605473; info:eu-repo/semantics/altIdentifier/wos/WOS:001200666500001; journal:INTERNATIONAL JOURNAL OF DERMATOLOGY; https://hdl.handle.net/10281/472099Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85190757563 |
| DOI: | 10.1111/ijd.17168 |
| الإتاحة: | https://doi.org/10.1111/ijd.17168Test https://hdl.handle.net/10281/472099Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.637CC79F |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/ijd.17168 |
|---|